Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bolt Biotherapeutics
Biotech
Atai, Eli Lilly, Novartis & more—Chutes & Ladders
Atai announces CEO transition plans. Lilly's Alonzo Weems will retire after 27 years. Novartis China President set to lead all ex-US commercial work.
Max Bayer
,
Gabrielle Masson
May 17, 2024 8:30am
Bolt Bio halves workforce, while Tenaya lays off 5th of staff
May 15, 2024 7:17am
Biotechs cut pipeline prospects to focus on priority programs
Aug 11, 2022 9:43am
Bolt cans candidate over toxicity, pauses work to extend runway
Aug 11, 2022 7:50am
Genmab joins with Bolt to develop bispecific immune stimulators
Jun 2, 2021 8:00am
Bolt Biotherapeutics strikes a major upsized $230M IPO
Feb 5, 2021 9:05am
